China approves Hengrui breast cancer drug on Phase II data

Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) said China’s State Drug Administration conditionally approved pyrotinib in combination with capecitabine to treat HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy. The product was under Priority Review.

Hengrui Medicine said pyrotinib is the first drug developed in China to receive conditional approval in the country to treat solid tumors...